Powerful Medical secures CPT code 1139T for Queen of Hearts AI ECG after FDA authorisation
Powerful Medical secures CPT code 1139T for Queen of Hearts AI ECG, opening a US billing pathway while reimbursement remains unresolved.
Powerful Medical secures CPT code 1139T for Queen of Hearts AI ECG, opening a US billing pathway while reimbursement remains unresolved.
Kivo Health raises $10m to expand virtual COPD care, backed by early rehabilitation outcomes and projected savings that still need validation.
Vincora gains FDA permission to study its NeXuS mitral repair system in the US, with procedural safety and lasting valve repair now in focus.
EQT agrees a €10.8 billion takeover of QIAGEN at €46.50 per share. Diagnostics growth, financing and shareholder approval remain key.
Johnson & Johnson advances Polyphonic surgical AI deployment in Abu Dhabi. Clinical validation, data governance and hospital adoption will shape its impact.
ZAP Surgical has secured $36 million in financing led by Catalio Capital Management, following shipment of its 50th ZAP-X system and treatment of nearly 10,000 patients worldwide. The investment will support manufacturing expansion and broader access to self-shielded brain radiosurgery.
GE HealthCare has introduced LOGIQ Focus, a general imaging ultrasound system combining cSound Architecture with automated scanning and workflow tools. In a third-party abdominal imaging study, the system completed scans 26% faster than a comparator, while 90% of participating physicians rated image quality highly.
Masimo has received FDA 510(k) clearance for atrial fibrillation detection on its Radius VSM monitor, reporting 97% sensitivity and 100% specificity in clinical validation. The feature joins an earlier-cleared respiratory depression algorithm, extending pulse oximetry into automated recognition of clinically important physiological patterns.
The FDA has approved satralizumab for adults with thyroid eye disease, introducing the first at-home subcutaneous treatment option. The decision follows two Phase 3 trials, one of which missed its primary endpoint, while the other demonstrated significant improvements in eye bulging and double vision.
Organon has reported a cumulative six-year Pearl Index of 0.93 and an estimated pregnancy rate of 3.9% for the hormone-free MIUDELLA intrauterine system. The findings support an FDA application to extend its approved use from three to six years, with a decision expected in the second quarter of 2027.